TrialBlood2014
Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy.
George Mulligan et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
70 papers cite itlatest 60 shown
this paperpooled ittrialcites it